A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy - Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00067782

Locations


United States, Arizona
	Local Institution
	Phoenix, Arizona, United States

United States, California
	Local Institution
	West Hollywood, California, United States

United States, District of Columbia
	Local Institution
	Washington, District of Columbia, United States

United States, Florida
	Local Institution
	Ft. Lauderdale, Florida, United States
	Local Institution
	Tampa, Florida, United States
	Local Institution
	Miami, Florida, United States
	Local Institution
	Altamonte Springs, Florida, United States

United States, Massachusetts
	Local Institution
	Boston, Massachusetts, United States

United States, Minnesota
	Local Institution
	Minneapolis, Minnesota, United States

United States, Missouri
	Local Institution
	St. Louis, Missouri, United States

United States, New Jersey
	Local Institution
	East Orange, New Jersey, United States

United States, New York
	Local Institution
	New York, New York, United States

United States, North Carolina
	Local Institution
	Huntersville, North Carolina, United States

United States, Ohio
	Local Institution
	Cleveland, Ohio, United States

United States, Oklahoma
	Local Institution
	Oklahoma City, Oklahoma, United States

United States, Pennsylvania
	Local Institution
	Philadelphia, Pennsylvania, United States

United States, South Carolina
	Local Institution
	Columbia, South Carolina, United States

United States, Texas
	Local Institution
	Houston, Texas, United States
	Local Institution
	Fort Worth, Texas, United States

Sponsors and Collaborators

Bristol-Myers Squibb

Investigators


Study Director:	Bristol-Myers Squibb	Bristol-Myers Squibb